Therapeutic potential of CMPP, a novel maleimide derivative, in a reserpine-induced mouse model of pain–depression dyad
Lorca Alzoubi, Yousra Bsieso, Omar Gammoh, Alaa A.A. Aljabali, Bader A. Salameh, Abdelrahim Alqudah, Esam Qnais, Ahmad M. Al-malkawi, Kayed Abu-Safieh · 2026
Read Therapeutic potential of CMPP, a novel maleimide derivative, in a reserpine-induced mouse model of pain–depression dyad by Lorca Alzoubi, Yousra Bsieso, Omar Gammoh, Alaa A.A. Aljabali, Bader A. Salameh, Abdelrahim Alqudah, Esam Qnais, Ahmad M. Al-malkawi, Kayed Abu-Safieh (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/PMC13292243.txt.
Description
Lorca Alzoubi and co-authors test a 2026 candidate drug, CMPP, in a mouse model where pain and depression arrive together. Reserpine, given for three days, creates that paired state by draining monoamine transmitters. Mice received CMPP at three doses or gabapentin, and the middle dose then fed into brain chemistry analyses.
Reserpine lowered paw withdrawal thresholds, raised immobility in the swim test, and slowed escape in a water maze. CMPP reversed each of those behavioral changes. In brain tissue it restored glutathione, cut oxidative damage markers, partly rebuilt serotonin and norepinephrine, lowered glutamate, and curbed MAO-A activity. Blood inflammation markers TNF-alpha and IL-1beta also fell. The authors back CMPP as a multi-target option for pain-depression overlap.
Catalog record
| CREATOR | Lorca Alzoubi, Yousra Bsieso, Omar Gammoh, Alaa A.A. Aljabali, Bader A. Salameh, Abdelrahim Alqudah, Esam Qnais, Ahmad M. Al-malkawi, Kayed Abu-Safieh |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 65847 |
| LICENSE | https://creativecommons.org/licenses/by/4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |